From the Guidelines
Glucagon-like peptide-2 (GLP-2) may have a potential role in the treatment of heart failure with preserved ejection fraction (HFpEF), although more research is needed to fully understand its effects. The current evidence suggests that GLP-2 may benefit HFpEF patients through improved intestinal barrier function, reduced systemic inflammation, and enhanced nutrient absorption, which could help address the metabolic abnormalities and inflammatory processes that contribute to HFpEF pathophysiology 1. Some studies have investigated the use of GLP-2 analogs, such as teduglutide, in patients with intestinal disorders, and these agents may have cardiovascular benefits in HFpEF patients 1. However, the typical dosing for teduglutide in HFpEF patients is still being established, and more research is needed to determine the optimal treatment protocol 1. Patients with HFpEF often have comorbidities like diabetes, obesity, and chronic kidney disease that could be positively affected by GLP-2 therapy, and the rationale behind GLP-2 use in HFpEF relates to the growing understanding of the gut-heart axis, where intestinal dysfunction contributes to systemic inflammation and cardiac stress 1. Key considerations for the use of GLP-2 in HFpEF include:
- The need for further research to fully understand the effects of GLP-2 on HFpEF outcomes
- The potential benefits of GLP-2 on intestinal barrier function, systemic inflammation, and nutrient absorption
- The importance of considering GLP-2 as part of a comprehensive treatment approach that includes standard HFpEF therapies, such as SGLT2 inhibitors, mineralocorticoid receptor antagonists, and lifestyle modifications 1. In terms of specific treatment recommendations, the 2022 AHA/ACC/HFSA guideline for the management of heart failure suggests that patients with HFpEF should be treated with a comprehensive approach that includes diuretics, identification and treatment of specific causes, and management of contributing comorbidities, although GLP-2 is not specifically mentioned as a recommended treatment 1. Overall, while GLP-2 may have a potential role in the treatment of HFpEF, more research is needed to fully understand its effects and to determine the optimal treatment protocol.
From the Research
Glp-2 in HFpEF
- There is no direct mention of Glp-2 in the provided studies related to HFpEF 2, 3, 4, 5, 6.
- The studies focus on the diagnosis, mechanisms, and management of HFpEF, discussing various aspects such as pathophysiology, diagnostic approaches, and treatment strategies 2, 3, 4, 5, 6.
- None of the studies explicitly mention the role of Glp-2 in HFpEF, suggesting a lack of direct evidence on this topic 2, 3, 4, 5, 6.
Related Concepts
- HFpEF is a complex syndrome characterized by preserved left ventricular ejection fraction, with a high prevalence and poor prognosis 2, 3, 4, 5, 6.
- The diagnosis of HFpEF can be challenging, and various approaches have been proposed, including the use of left atrial volume and natriuretic peptides 5.
- Treatment strategies for HFpEF are limited, and current therapies focus on managing symptoms and comorbidities, with a need for more effective treatments 2, 3, 4, 6.